Shattuck Labs’ (STTK) Buy Rating Reaffirmed at Needham & Company LLC

Shattuck Labs (NASDAQ:STTK)‘s stock had its “buy” rating reissued by equities researchers at Needham & Company LLC in a research note issued to investors on Friday, Benzinga reports. They presently have a $8.00 price target on the stock. Needham & Company LLC’s price target would suggest a potential upside of 112.20% from the company’s previous close.

Several other research analysts have also recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Shattuck Labs in a research note on Friday. BTIG Research lowered shares of Shattuck Labs from a “buy” rating to a “neutral” rating in a research report on Monday, June 17th. Finally, Citigroup dropped their price target on shares of Shattuck Labs from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, June 17th.

Shattuck Labs Stock Performance

Shattuck Labs stock opened at $3.77 on Friday. Shattuck Labs has a one year low of $1.33 and a one year high of $11.76. The company has a 50-day simple moving average of $5.09 and a 200-day simple moving average of $7.85. The firm has a market capitalization of $179.26 million, a P/E ratio of -1.95 and a beta of 1.73.

Shattuck Labs (NASDAQ:STTK) last posted its earnings results on Thursday, May 2nd. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.08. The firm had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $0.30 million. Shattuck Labs had a negative net margin of 3,133.63% and a negative return on equity of 64.85%. The business’s revenue for the quarter was up 2200.0% on a year-over-year basis. As a group, sell-side analysts forecast that Shattuck Labs will post -1.56 earnings per share for the current year.

Insider Transactions at Shattuck Labs

In other news, CEO Taylor Schreiber bought 14,400 shares of the stock in a transaction that occurred on Wednesday, June 26th. The shares were purchased at an average cost of $3.47 per share, with a total value of $49,968.00. Following the completion of the acquisition, the chief executive officer now directly owns 34,502 shares in the company, valued at $119,721.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 10.50% of the company’s stock.

Institutional Trading of Shattuck Labs

A number of large investors have recently added to or reduced their stakes in STTK. Vanguard Group Inc. increased its holdings in shares of Shattuck Labs by 38.2% in the first quarter. Vanguard Group Inc. now owns 1,819,926 shares of the company’s stock valued at $16,270,000 after buying an additional 502,860 shares in the last quarter. Franklin Resources Inc. acquired a new position in shares of Shattuck Labs in the 4th quarter worth $11,663,000. Pinnacle Associates Ltd. raised its position in shares of Shattuck Labs by 15.0% during the second quarter. Pinnacle Associates Ltd. now owns 599,423 shares of the company’s stock worth $2,314,000 after purchasing an additional 78,177 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Shattuck Labs by 209.7% during the second quarter. Bank of New York Mellon Corp now owns 222,034 shares of the company’s stock valued at $857,000 after purchasing an additional 150,340 shares during the last quarter. Finally, Ritholtz Wealth Management lifted its holdings in shares of Shattuck Labs by 57.4% during the second quarter. Ritholtz Wealth Management now owns 142,540 shares of the company’s stock valued at $550,000 after purchasing an additional 52,000 shares during the last quarter. 58.74% of the stock is currently owned by institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.